Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress

Details for the poster presentations:

Abstract Title: Development of a platform gene therapy approach for Congenital Myasthenic Syndromes
Presenting Author: Patricio V. Sepulveda S., PhD MBA
Date: Tuesday, October 22, 2024 

Abstract Title: Pre-clinical development of gene augmentation therapy to restore Acetylcholinesterase activity in Collagen Q Congenital Myasthenic Syndrome using a platform approach to AAV gene therapy development.
Presenting Author: Claudia Canzonetta, PhD
Date: Tuesday, October 22, 2024 

Abstract Title: The pre-clinical development of gene augmentation therapy to stabilize the neuromuscular junction in Dok-7 Congenital Myasthenic Syndrome reveals a mechanism of action that has the potential to treat many neuromuscular junction diseases using the same vector.
Presenting Author: Paul Al Hawkins
Date: Wednesday, October 23, 2024

About Amplo Biotechnology

Amplo is a late, pre-clinical genetic medicines company focused on therapies for rare and super-rare diseases.

View original content:https://www.prnewswire.co.uk/news-releases/amplo-biotechnology-announces-three-presentations-at-the-european-society-of-gene-and-cell-therapy-31st-annual-congress-302279179.html